Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 17/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2726359 | 0.83 | KCNH2 (0.61) | KCNJ1KCNH2 | |
| SCHEMBL2724588 | 0.82 | KCNJ1 (0.41) | KCNJ1KCNH2CHRM4 | |
| SCHEMBL2731395 | 0.75 | KCNJ1 (0.56) | KCNJ1KCNH2CHRM4 | |
| SCHEMBL2731587 | 0.72 | KCNJ1 (0.61) | KCNJ1KCNH2 | |
| SCHEMBL2722709 | 0.72 | KCNH2 (0.60) | KCNJ1KCNH2HRH3 | |
| SCHEMBL15191890 | 0.71 | KCNJ1 (0.49) | KCNJ1KCNH2CHRM4 | |
| SCHEMBL21996912 | 0.68 | S1PR5 (0.40) | HRH3 | |
| SCHEMBL10234055 | 0.68 | KCNJ1 (1.00) | KCNJ1KCNH2 | |
| SCHEMBL2076961 | 0.68 | MAPK1 (0.37) | — | |
| SCHEMBL3773661 | 0.68 | AGTR2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632465-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9073882-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2632465-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | disclosed |
| WO-2012058116-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225561-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | KCNJ1 2/4885KCNH2 16/4885HRH3 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.